Introduction to current and future protein therapeutics: a protein engineering perspective.
about
Synthesis of heterobifunctional protein fusions using copper-free click chemistry and the aldehyde tagSite-Specific PEGylation of Therapeutic ProteinsDecoding mechanisms by which silent codon changes influence protein biogenesis and functionTo fuse or not to fuse: what is your purpose?Improving biophysical properties of a bispecific antibody scaffold to aid developabilityAdhiron: a stable and versatile peptide display scaffold for molecular recognition applicationsBiopharmaceuticals from microorganisms: from production to purificationEngineering Translation in Mammalian Cell Factories to Increase Protein Yield: The Unexpected Use of Long Non-Coding SINEUP RNAsRationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 DiabetesDissection of agonistic and blocking effects of CD200 receptor antibodiesRecent Advances in Application of Pharmacogenomics for BiotherapeuticsLinker length matters, fynomer-Fc fusion with an optimized linker displaying picomolar IL-17A inhibition potency.NanoScript: a nanoparticle-based artificial transcription factor for effective gene regulation.Engineering bispecificity into a single albumin-binding domain.Smart Release Nano-formulation of Cytochrome C and Hyaluronic Acid Induces Apoptosis in Cancer Cells.Development, optimization, and validation of novel anti-TEM1/CD248 affinity agent for optical imaging in cancerAnti-tat Hutat2:Fc mediated protection against tat-induced neurotoxicity and HIV-1 replication in human monocyte-derived macrophagesPCSK9 prosegment chimera as novel inhibitors of LDLR degradation.Retargeting T cells for HER2-positive tumor killing by a bispecific Fv-Fc antibody.Site-specific Labeling of a Protein Lysine Residue By Novel Kinetic Labeling Combinatorial Libraries.Discovery of binding proteins for a protein target using protein-protein docking-based virtual screening.Weak protein interactions and pH- and temperature-dependent aggregation of human Fc1.A systematic study of glycopeptide esterification for the semi-quantitative determination of sialylation in antibodies.Therapeutic antibodies against cancer.Rational design of antibodies targeting specific epitopes within intrinsically disordered proteins.Kinetic Controlled Tag-Catcher Interactions for Directed Covalent Protein Assembly.A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.Application of strain-promoted azide-alkyne cycloaddition and tetrazine ligation to targeted Fc-drug conjugates.Challenges in design and characterization of ligand-targeted drug delivery systems.A synonymous codon change alters the drug sensitivity of ΔF508 cystic fibrosis transmembrane conductance regulator.Streamlined expressed protein ligation using split inteins.Covalent Incorporation of Trehalose within Hydrogels for Enhanced Long-Term Functional Stability and Controlled Release of Biomacromolecules.Effects of protein transduction domain (PTD) selection and position for improved intracellular delivery of PTD-Hsp27 fusion protein formulationsMolecular approaches for improved clotting factors for hemophilia.Cell-penetrating peptides meditated encapsulation of protein therapeutics into intact red blood cells and its application.Using antibodies to target cancer therapeutics.Molecular engineering of antibodies for therapeutic and diagnostic purposes.Fc-fusion proteins: new developments and future perspectives.Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies.Antigen generation and display in therapeutic antibody drug discovery -- a neglected but critical player.
P2860
Q24601129-0A749EBE-C3B5-4BC0-A4BA-9A58B1F00D5FQ26777819-AD6380A4-4978-4776-990B-8DC5873145ABQ26821951-157DBC33-C293-4266-A99C-D9B4D2716AF3Q26991608-CDE5EA69-0CD5-457B-9A86-CB05AC0AB055Q27679445-3FC132F1-CA78-4D15-9B66-56F4498FB909Q27682484-BE3F6C4F-C069-4EB2-949A-3DD0C6AC99F6Q28066997-EE836D38-3C0F-459F-AD55-E6875DAA4059Q28071440-044247CD-E455-4998-8984-FE8F1BFFB110Q28485340-12BDA087-3AD7-406E-AB19-5E57E9ACC025Q28488034-1E5D14E9-A6B5-4AF3-AD0A-D6240A9613C4Q29247996-7F2146A7-9FDC-4676-BF6B-A3A5EBBCA39AQ30009438-EF616D68-D82C-4A5D-A497-BE1198E0589CQ30587595-418BACF9-3903-4F66-851E-0F210AB01601Q31032588-DE46BACF-6F79-4124-9204-D10917FE2F42Q33894458-ACA3C25C-F176-4E8E-AC79-711309BBB6F0Q34334475-7A1C0414-F390-4245-8F1F-3D8E5B49909DQ34632979-29D05B5E-C8B6-4B85-A663-62700F3265B1Q34951227-006A383D-5740-4E9A-AC4F-0BC6808DD388Q35005791-CA1B4A13-B6F0-4C32-BB16-E21ABA2D1774Q35155487-C0AEE8DC-D12B-4658-B587-CED2E30532DEQ35172930-1DF1F980-14D7-4E29-956D-5F5A9664E7FDQ35743857-70723A5E-3601-4EC1-9A84-9BF44B1E0196Q35762130-81130A96-C0E0-4A90-96A7-84C8AA75C928Q35908498-69889FEF-93BA-4F40-93FD-6BD04BA4992CQ35961236-C380405B-F69A-48BA-A3FD-3C89BE9D6C06Q36175045-E14BF8A2-6A31-46DE-9E69-9A163E6CF584Q36211427-08E6CCC9-B265-4668-9088-1745EF65D396Q36328501-13D37360-AD32-4A82-8BBD-95DB9837D98CQ36346851-F5375B55-09B5-4A27-9E0C-53BC916BA241Q36385376-8739F6C6-D40D-4557-90C2-EACCB1A1821AQ36530093-66BED4F0-7D67-497A-BFA1-60AE2815ADE8Q36781510-001E69BE-F6C8-4759-BA9B-823E3442DB83Q37284677-B1BD47A4-04A6-4831-B953-BD3E7EE908C0Q37334700-70A4B7A0-91F9-48FE-8A7F-8C03AF7C262BQ37612333-ADAF634E-A1A8-4630-8921-9AD8790A61ACQ38014920-D8D27D69-44B9-4F1F-9BE6-C101272ED3B6Q38017581-82AE96C3-7C92-4CDA-B4FB-783C157B2EC5Q38029985-26062D94-12DF-4167-B843-BB2D9D7DB44CQ38038410-7B98545F-370B-4A72-A31D-FFA326B5E05EQ38058763-E735B908-6770-481D-A4C4-0F7B639CE191
P2860
Introduction to current and future protein therapeutics: a protein engineering perspective.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Introduction to current and fu ...... otein engineering perspective.
@ast
Introduction to current and fu ...... otein engineering perspective.
@en
Introduction to current and fu ...... otein engineering perspective.
@nl
type
label
Introduction to current and fu ...... otein engineering perspective.
@ast
Introduction to current and fu ...... otein engineering perspective.
@en
Introduction to current and fu ...... otein engineering perspective.
@nl
prefLabel
Introduction to current and fu ...... otein engineering perspective.
@ast
Introduction to current and fu ...... otein engineering perspective.
@en
Introduction to current and fu ...... otein engineering perspective.
@nl
P1476
Introduction to current and fu ...... otein engineering perspective.
@en
P2093
Paul J Carter
P304
P356
10.1016/J.YEXCR.2011.02.013
P407
P577
2011-03-01T00:00:00Z